Product Description: Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935./[2]Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. /[3]Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61.
CAS Number: 2136633-23-1
Molecular Weight: 149000 (average)
Compound Purity: 99.0
Research Area: Cancer
Solubility: H2O
Target: Antibody-Drug Conjugates (ADCs);EGFR
English
Deutsch
